Skip to main navigation

Home
Engineered with Purpose
- The History of Synthetic Biology
Living Medicines
- Designing Synthetic Biotics
Pipeline
- Partner with Us
Clinical Trials
Our People
Investors + Media

explore the
possibilities

Synlogic Therapeutics

Investor Relations

IR menu

Overview
News
News Releases In the News
Events & Presentations
Events Presentations
Publications
Stock Information
Stock Quote & Chart Analyst Coverage
Corporate Governance
Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix
Financials
SEC Filings Quarterly Results
Investor Resources
FAQs Contact IR Email Alerts RSS Feeds

In the News

Home
Engineered with Purpose
- The History of Synthetic Biology
Living Medicines
- Designing Synthetic Biotics
Pipeline
- Partner with Us
Clinical Trials
Our People
Investors + Media

Source

BioProcess International

Using Synthetic Biology To Develop Novel Biotherapeutics

December 12, 2022

Using Synthetic Biology To Develop Novel Biotherapeutics

Source

Endpoints News

FDA remains silent on orphan drug exclusivity after last year's court loss

December 1, 2022

FDA remains silent on orphan drug exclusivity after last year's court loss

Source

Nature

Seeking therapeutic opportunities amid the complexity of the microbiome

November 24, 2022

Seeking therapeutic opportunities amid the complexity of the microbiome

Source

Biocentury

Phenylketonuria pipeline breaks into new modalities

November 23, 2022

Phenylketonuria pipeline breaks into new modalities 478.5 KB

Source

WIRED

This Gulp of Engineered Bacteria Is Meant to Treat Disease

November 7, 2022

This Gulp of Engineered Bacteria Is Meant to Treat Disease

Source

CheckRare

Can a Probiotic Help PKU Patients?

November 7, 2022

Can a Probiotic Help PKU Patients?

Source

Global Genes

Synlogic Reports Positive Top-Line Phase 2 Results in PKU

October 19, 2022

Synlogic Reports Positive Top-Line Phase 2 Results in PKU

Source

pharmaphorum

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

October 19, 2022

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

Source

The Pharma Letter

Following positive Phase II data, Synlogic advances SYNB1934 to Phase III

October 19, 2022

Following positive Phase II data, Synlogic advances SYNB1934 to Phase III

Source

HCP Live

New Rare Disease Therapy Effectively Lowers Plasma Phe in Patients with PKU

October 18, 2022

New Rare Disease Therapy Effectively Lowers Plasma Phe in Patients with PKU

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Next page
Last page

Investor Resources

Contact IR
Investor FAQs
RSS Feeds

Investor Email Alerts

Email

Contact

Synlogic

301 Binney St #402
Cambridge, MA 02142

info@synlogictx.com
(617) 401-9975

Twitter
LinkedIn
Youtube
Facebook
Instagram

Privacy and Terms

© 2023 Synlogic
Privacy Policy